🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the pathogen, according to scientists.

A Global Challenge

Cases of gonorrhoea are increasing around the world, with figures suggesting over 82 million instances per year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the reality of growing infection rates, the spread of superbugs and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This milestone signifies a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Results and Worldwide Availability

According to results detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which combines two antibiotics. The research enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed hope. The availability of a easy-to-administer therapy of this kind is seen as a "game-changer" for public health efforts. This is considered essential to reduce the burden of the disease for patients and to halt the transmission of extremely resistant gonorrhoea around the world.